Jerusalem, 3 June, 2025 (TPS-IL) — Israel’s Nasus Pharma has announced positive Phase 2 results for its intranasal Epinephrine powder (NS002), published in the peer-reviewed The Journal of Allergy and Clinical Immunology: Global. The study, done at Hadassah Medical Center in Jerusalem, showed that a 4 mg nasal spray dose worked faster and was absorbed better than a standard Epinephrine autoinjector.
Within six minutes, 91% of participants reached effective levels, compared to 55% using the injection. The product was safe, easy to use, and stable at room temperature for up to five years. NS002 may offer a simple, needle-free option for treating life-threatening allergic reactions.